Search
China Approves Encorafenib Capsule and Cetuximab Combination Therapy for Second-Line Treatment of BRAF V600E Mutant Metastatic Colorectal Cancer
6 day ago /
Read about 0 minute
Author：小编
The National Medical Products Administration of China has granted approval for the combination therapy of Encorafenib Capsule (Braftovi) and Cetuximab for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer who have previously undergone systemic therapy. This innovative treatment regimen is expected to markedly enhance the overall survival rate of patients and substantially decrease the risk of mortality.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
